Recent Company News

• 01:09 AM ET Sep 18, 2025
  

  UCB announces new 12-week efficacy and 18-week safety data from Phase 1/2a first-in-patient trial for galvokimig (€203.00, 0.00)

• 01:14 AM ET Sep 17, 2025
  

  UCB's announces BIMZELX data in moderate-to-severe plaque psoriasis at EADV (€203.90, 0.00)

• 09:35 AM ET Sep 16, 2025
  

  FDA publishes dozens of Untitled Letters sent to public biopharma companies

• 08:39 AM ET Sep 11, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 11:54 AM ET Sep 12, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 14-Sep

• 04:45 PM ET Sep 10, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 03:56 AM ET Sep 10, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (67 total)

• 03:51 AM ET Sep 08, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (50 total)